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Introduction
Patients with breast carcinomas can display a different
response to therapy and clinical outcome despite sim-
ilar stage and grade of disease. Gene expression profil-
ing using microarray technology has recently allowed
the identification of subgroups of breast carcinomas
with distinct molecular signatures and biologic behav-
ior. Targeted therapy with tamoxifen (1) and herceptin
(2) is available for estrogen receptor–positive (ER-pos-
itive) and Her-2–overexpressing breast tumors, respec-
tively. ER-negative breast carcinomas have been fur-
ther classified by molecular profiling into at least two
biologically different subtypes. These include Her-
2–positive as well as Her-2–negative tumors with a
basal-like phenotype (3, 4). This latter group of ER-
negative, Her-2–negative tumors expressing genes
associated with a basal-like phenotype typically shows
resistance to standard treatments and is characterized
by aggressive biologic behavior.
F-box proteins (Fbp’s) are characterized by an approx-
imately 40–amino acid domain called F-box because it
was first identified in cyclin F (5). Studies involving sev-
eral organisms have shown that Fbp’s play a crucial role
in the ubiquitin-mediated degradation of cellular reg-
ulatory proteins (e.g., cyclins, cdk-inhibitors, β-catenin,
IKB, etc.) (reviewed in refs. 6–8). Indeed, Fbp’s are sub-
units of ubiquitin ligases named SCFs because they are
formed by the following basic subunits: S-phase kinase-
associated protein 1 (Skp1), Cul1, Roc1/Rbx1, and one
of many Fbp’s. Since the substrate specificity of SCF
ligases is dictated by different Fbp’s that act as sub-
strate-targeting subunits, a large number of Fbp’s is
necessary to ensure highly specific substrate recogni-
tion. In fact, large families of Fbp’s are present in all
eukaryotes (e.g., 11 members in yeast, 29 members in
flies, and at least 54 in mammals; refs. 9–11).
Human Skp1 and the F-box protein Skp2 were origi-
nally identified as two proteins physically interacting
with cyclin A and therefore were designated as S-phase
kinase-associated proteins (12). We and others have
demonstrated that Skp2 is required for the ubiquiti-
nation and consequent degradation of the cdk
inhibitor p27 both in vivo (13, 14) and in vitro (13, 15).
Skp2-deficient mice grow slower than littermate con-
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trols and show smaller organs, with all tissues contain-
ing decreased numbers of cells (16). Skp2–/– cells show
high levels of p27, polyploidy, and centrosome overdu-
plication. This phenotype underscores the importance
of Skp2 in positively regulating cell proliferation. All
cellular and histopathological abnormalities observed
in Skp2-deficient mice are abolished in Skp2/p27 dou-
ble-knockout mice, indicating that p27 is a primary
substrate of Skp2.
A decrease in the level of p27 protein in the absence
of alteration of the p27 gene is commonly seen in
many human cancers, including epithelial cancers,
brain tumors, and lymphoproliferative neoplasms
(reviewed in ref. 17). Importantly, reduced levels of p27
correlate with poor prognosis. In colon cancers (18),
non–small cell lung cancers (19), oral squamous cell
carcinomas (20), lymphomas (21), and astrocytic brain
tumors (22), this decrease in p27 protein levels has
been shown to be due to an increase in its ubiquitin-
proteasome–mediated proteolysis. One possible rea-
son for this enhanced degradation might lie in the
presence of high levels of Skp2. Accordingly, it has
been shown that unregulated Skp2 expression induces
p27 degradation and entry into S-phase, both in the
presence of low serum concentration (14) and in the
absence of cell adhesion (23). Indeed, it has been
shown recently that Skp2 has oncogenic potential (24,
25) and is overexpressed in oral epithelial (20, 24), col-
orectal carcinomas (26), and lymphomas (25, 27).
Because p27 is downregulated in aggressive human
breast cancers (28–30), and because of the role of Skp2
in p27 degradation, we have assessed the levels of Skp2
and p27 in human breast cancer samples and per-
formed experiments to evaluate the role of Skp2 in
breast cancer cell lines. Our data support an oncogenic
role for Skp2 and suggest it may be a therapeutic target
in a subset of ER-negative, Her-2–negative human
breast cancers with a basal-like phenotype that is typi-
cally resistant to standard therapies.
Methods
Patient populations. In sample set A (oligonucleotide
microarray analysis), a total of 90 primary, untreated,
breast carcinoma frozen tissue samples were selected
from a repository held by the Dana-Farber/Harvard
Specialized Program of Research Excellence in Breast
Cancer. Histologic sections of tumor were blindly
reviewed and scored for a modified Bloom-Richardson
grade. Hormone receptor and Her-2 receptor immuno-
histochemical sections (performed for clinical assess-
ment) were reviewed and scored as positive or negative.
For sample set B (immunohistochemistry and immuno-
fluorescence analysis), breast cancer specimens from the
years 1987–1996 were retrieved from the files of the
Department of Oncology Azienda Unità Sanitaria
Locale, Rimini, Italy. Eighty-four patients with breast
carcinoma were selected for the study. All the patients
developed either local recurrences or metastatic disease
(nodal or distant) during the follow-up period. Stage
and grade were available in all cases. The median follow-
up for survivor patients was 40 months.
Oligonucleotide microarray analysis. The frozen bulk
tumor samples (sample set A) were confirmed to contain
at least 70% viable tumor by area on histologic thin sec-
tions. Total RNA extracted from frozen tissue was used
to generate biotinylated cRNA target and subsequently
hybridized to Affymetrix U95A oligonucleotide probe
arrays (Affymetrix Inc., Santa Clara, California, USA),
according to standard protocols (31). Raw expression
values were obtained using GENECHIP software from
Affymetrix and further analyzed using the DNA-Chip
Analyzer (dChip) custom software. Of the 90 arrayed
samples, one array was excluded for a gross defect
(scratch), leaving 89 tumors for analysis. Hierarchical
clustering was performed using the dChip software. The
clustering diagram in Figure 1a was performed using a
subset of 2,130 genes filtered for those showing a varia-
tion of expression across the samples. The filtering cri-
teria included genes with a coefficient of variation
(SD/mean) between 0.65 and 10.0 and with a mean
intensity value of greater than 50 units in at least 5% of
the tumor samples. The smaller clustering diagram in
Figure 1b was performed using a smaller set of 41 genes
selected to show the correlation between the expression
of Skp2, cell cycle regulatory genes, hormone receptors
and related genes, Her-2 amplicon genes, keratin genes,
and several markers of the basal cell phenotype.
Immunohistochemistry and immunofluorescence. Both p27
and Skp2 expression was assessed in all 84 tumor sam-
ples (sample set B), while Ki67 expression was investi-
gated in a subset of 37 tumors. Immunohistochemistry
experiments were performed as described previously
(32). The following primary Ab’s were used: anti-Skp2
(Zymed Inc., South San Francisco, California, USA) at
1:100 dilution as described (25), anti-p27 (Transduction
Laboratories, Lexington, Kentucky, USA) at 1:200 dilu-
tion, anti-Ki67 (Immunotech, Westbrook, Maine, USA)
at 1:50 dilution, anti-ER (DAKO Corp., Carpinteria, Cal-
ifornia, USA) at 1:100 dilution, and anti-Her-2 (AO485;
DAKO Corp.) at 1:200 dilution.
Scoring of immunostained slides was done accord-
ing to the percentage of tumor cells exhibiting nuclear
(p27, Ki67, and ER) or nuclear/cytoplasmic staining
(Skp2). To define high and low p27 expressors we used
a cutoff of 50% or more positive tumor cells, which is
the cutoff used in the majority of the previous studies.
To select a cutoff for Skp2 we tried first the mean and
the median. Because the majority of patients had low
levels of Skp2, using either the mean or the median as
a cutoff would have included cases with a low per-
centage of positive cells in the high expressor catego-
ry. To have a more meaningful classification, we estab-
lished the cutoff in the 75th percentile (10% or more
of positive cells). A cutoff of 10% or more was used to
define ER-positive cases. Fisher’s exact test was used to
assess the association between Skp2 and p27 expres-
sion levels. Linear regression analysis was used to
assess the association between Skp2 and Ki67 expres-
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Figure 1
Hierarchical clustering of 89 breast tumor samples
(sample set A). Each column represents a tumor sam-
ple, and each row represents a different gene probe set.
The relative expression level of the genes in the samples
is indicated by a gradient of color, with blue represent-
ing expression levels below the mean and red repre-
senting expression levels above the mean. The tumors
are clustered in the dendrogram at the top, and the
genes are clustered in the dendrogram down the side.
Tumors and genes appearing next to each other are
more similar in expression pattern. The pathologic
data for each tumor sample is represented by the color
bars below the tumor dendrograms: dark blue, modi-
fied Bloom-Richardson grade III; light blue, modified
Bloom-Richardson grade I or II; dark green, ER and PR
positive; light green, ER and PR negative; dark purple,
Her-2 overexpressed (3+); light purple, Her-2 nonover-
expressed. The tumor clusters showing the highest lev-
els of Skp2 expression and the gene clusters that
include the Skp2 gene are highlighted in orange. (a)
Hierarchical clustering of 89 tumors for 2,130 filtered
genes. (b) Clustering of 89 tumors to demonstrate rel-
ative expression of 41 selected genes, including cell
cycle regulatory genes (e.g., cyclins, Cdks, Cks1, Cks2,
PCNA, p16), keratins, hormone receptors (e.g., ERα,
ERβ, ERRα, androgen receptor), ER-associated genes
(e.g., HNF3, TFF3, GATA3, LIV-1), Her-2 amplicon
genes (e.g., Her-2, PPAR-binding protein, MLN64,
GRB7), and genes associated with the basal-like tumor
subgroup (e.g., UDP-N-Ac-galactosamine, chitinase 
3-like 2, P-cadherin, AC133/prominin-like 1, HDGF).
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sion levels. Stage and grade of the tumors were com-
pared with Skp2 and p27 dichotomized expression lev-
els using Fisher’s exact test. The proportional hazards
model was used to assess the association of Skp2 and
p27 with survival time, controlling for stage and grade
of the tumor.
Both the breast carcinoma cell line MCF-7 (Ameri-
can Type Culture Collection, Rockville, Maryland,
USA) and five paraffin-embedded breast carcinoma
samples from sample set B were submitted to double-
immunofluorescence staining for Skp2/Ki67. Double-
immunofluorescence experiments were performed as
described previously (33).
Cell cultures, cell synchronization, and cell cycle analysis.
Human breast cancer cell lines (MCF-7 and MDA-
MB-435), human breast cell line HBL-100 (expressing
SV-40 large T protein), human fibrosarcoma cell line
HS-913-T, and human embryonic kidney adenovirus–
and SV-40 large T–transformed epithelial cell line 293
were obtained from the American Type Culture Col-
lection and cultured as described (34). Normal human
breast ductal epithelial cells (HBECs) were obtained
from Clonetics/BioWhittaker Inc. (Walkersville,
Maryland, USA) and cultured in the growth medium
recommended by the manufacturer as described (34).
Human normal diploid fibroblasts (HF, also called
IMR-90) and SV-40 large T–transformed IMR-90
(IDH-4) were grown as described (34).
To test the effects of lack of adhesion to the ECM,
cells were trypsinized and reseeded on Petri dishes
coated with 1% agarose (suspension) using 0.5 × 106 to
1 × 106 cells per 10-cm dish. Colony formation in soft
agar was done as described (23). For cell cycle analyses,
adherent cells were grown on glass coverslips, labeled
for 5 hours with 10 µm bromodeoxyuridine (BrdU),
rinsed with PBS, and fixed for 10 minutes in –20°C
methanol-acetone (1:1). Fixed cells were stained for
BrdU and quantified as described previously (35).
Retroviral-mediated gene transfer. Packaging GP-293
cells (CLONTECH Laboratories Inc., Palo Alto, Cali-
fornia, USA) were transfected with retroviral plasmids
according to the manufacturer’s instructions. Forty-
eight hours after transfection, the virus-containing
medium was collected and supplemented with 8
µg/ml polybrene (Sigma-Aldrich, St. Louis, Missouri,
USA). Then, the culture medium of the target cells was
replaced with this viral supernatant for 24 hours. After
a 12-hour recovery in normal medium, the infection
process was repeated a second time with Skp2, cyclin
D1, and cyclin E viruses, and three to four times with
Skp2(∆F) virus. The percentage of infected cells was
quantified by flow cytometry or immunofluorescence.
In all cases, greater than 85% of the cells were infected.
Multiple genes were introduced sequentially.
Results
Skp2 message is highly expressed in a subgroup of ER-nega-
tive and Her-2–negative tumors by oligonucleotide microar-
ray analysis. The 89 arrayed primary breast tumor sam-
ples (sample set A) were first analyzed by hierarchical
clustering using a filtered set of 2,130 variably
expressed genes (Figure 1a). The 89 tumors are clus-
tered across the top and the genes are clustered down
the side, based on similar patterns of expression. The
gene cluster that includes Skp2 is highlighted in
orange in the horizontal dendrogram. The tumor
cluster that shows the highest levels of expression of
Skp 2 is highlighted in orange in the vertical dendro-
gram. The histologic tumor grade and the results of
the immunohistochemistry analysis, ERs and proges-
terone receptors (ERs/PRs) and Her-2 proteins, are
represented by the blue, green, and purple color bars,
respectively. First, higher levels of Skp2 mRNA (> 0.3-
fold over the mean expression level) were more fre-
quently observed in ER-negative tumors (11 of 18 or
61%) than in ER-positive cases (16 of 71 or 23%). Sec-
ond, as shown in Figure 1a, the highest Skp2 expres-
sion levels were in a small subgroup of five tumors
that were all high grade, negative for ERs/PRs, and
negative for Her-2 overexpression. When compared
with the other samples, the tumor subset with high
Skp2 expression was noted to have higher relative
expression of other proliferation-associated genes and
a number of genes described previously to character-
ize a basal-like subset of breast tumors (3, 4). To bet-
ter visualize the correlation between the expression of
some of these genes, we performed cluster analysis of
the 89 tumors in a more limited gene space of 41
genes (Figure 1b). The 41 genes were selected to
include Skp2, other cell cycle regulatory genes, hor-
mone receptor genes, ER-regulated and ER-associated
genes, genes from the Her-2 amplicon, keratins, and
representative genes associated with the previously
described basal-like tumor subgroup. In this more
limited and selected gene space, there were now six
tumors in the cluster characterized by high Skp2
expression (cluster highlighted in orange). The high
Skp2 cluster included the 5 ER-, PR-, and Her-2–neg-
ative, high-grade cases that previously clustered
together in the larger gene space, plus an additional
ER/PR-negative, Her-2–negative, high-grade tumor. As
shown in Figure 1b, the high-Skp2 tumor cluster was
characterized by high expression of other genes encod-
ing proteins known to physically interact with Skp2:
cyclin A2, cyclin E1, Cdk2, and Cks1. In addition,
markers of S-phase, such as proliferating cell nuclear
antigen (PCNA), and G2/M, such as cyclin B1 and
Cks2, were also high in this subgroup. Not all cyclins,
however, clustered with Skp2. For example, cyclin D1
and cyclin D2, two cyclins known to play an impor-
tant role for the proliferation of breast epithelium,
were not highly expressed in this subset. In contrast,
cyclin D3 and Skp2 showed a similar expression pat-
tern. Finally, the tumor subset with high Skp2 levels
also showed expression of genes characteristic of the
basal-like breast cancer subgroup described by Sorlie
et al. (4), including keratin 5, keratin 17, UDP-N-Ac-
galactosamine, chitinase 3-like 2, and P-cadherin.
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High levels of Skp2 protein are associated with ER negativ-
ity, low expression of p27, high proliferation rate, and poor
survival. We then compared the results of the microar-
ray analysis with an immunohistochemical study in a
separate series of 84 breast carcinomas (sample set B),
for which follow-up data were also available. We ana-
lyzed levels of Skp2, p27, Ki67, and ER proteins. Skp2-
positive cells ranged from 0% to 35% (median 4%) in
the breast carcinoma samples (Figure 2g), whereas nor-
mal breast epithelium was consistently negative for
Skp2 expression (Figure 2, b,d, and f). Expression lev-
els ranged from 0% to 90% (median 40%) for p27, 0% to
70% (median 15%) for Ki67, and 0% to 90% for ER.
When cutoff points were used to categorize high and
low expressors, breast carcinoma cases showed three
major patterns of Skp2/p27 expression (Figure 2g).
Thirty tumors (36%) were characterized by high p27
and low Skp2 levels. Twenty-one tumors (25%)
expressed low p27 and high Skp2 levels. In 32 tumors
(38%), both low p27 and low Skp2 levels were observed.
Only one tumor expressed both high p27 and high
Skp2 levels. Fisher’s exact test showed that the per-
centage of high Skp2 expressors was significantly
greater in the group with low p27 expression (37%)
than in the group with high p27 expression (3%) 
(P < 0.001). In addition, we found that high levels of
Skp2 protein were more frequently observed in ER-
negative tumors (12 of 18 or 67%) than in ER-positive
cases (7 of 47 or 15%) (Fisher’s exact test, P < 0.0001)
and in tumors with high proliferation index (Ki67 pos-
itive) (Figure 3, a–d). Simple regression analysis
demonstrated a direct linear association between Skp2
and Ki67 expression levels (R2 = 0.84) (Figure 3e). We
further investigated whether Skp2 and Ki67 proteins
were expressed in the same subset of tumor cells. To
this end, double-immunofluorescence experiments for
Skp2 and Ki67 were performed both in breast cancer
MCF-7 cells and in paraffin-embedded tumor samples.
In both cases, Skp2 protein was detected only in cells
expressing Ki67 (Figure 3, f–k). Both Ki67 and Skp2
were localized in the nucleus. A subset of cells that
expressed Ki67 protein was negative for Skp2 expres-
sion, indicating that, as already shown for lymphomas
(27), levels of Skp2 might define the fraction of Ki67
cells that are in S-phase.
Finally, we looked at the relationship between Skp2
and survival. There was a statistically significant asso-
ciation between Skp2 expression levels and grade (Fish-
er’s exact test, P < 0.001). The Cox regression model
showed that high expression levels of Skp2 were asso-
ciated with poor survival (calculated from the time of
the first recurrence) in the univariate model [hazard
ratio = 2.83, 95% confidence interval = (1.48 – 5.44), 
P = 0.02]. When grade was added to this model, Skp2
still showed a trend toward discrimination of biologic
behavior [(hazard ratio = 1.71, 95% confidence interval
= (0.83 – 3.50)], although this was not statistically sig-
nificant. As expected, high values of p27 expression
were associated with better survival [hazard ratio =
0.37, 95% confidence interval = (0.16 – 0.84), P = 0.018]
in the univariate analysis. When stage, grade, or Skp2
were added into the model one at a time, similar to
Skp2, p27 also showed a trend in predicting survival
(hazard ratio = 0.5) but was no longer statistically sig-
nificant. These results indicate that larger number of
patients, with more statistical power, need to be inter-
rogated to establish if Skp2 is an independent predic-
tor of biologic behavior.
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Figure 2
Relationship between Skp2 and p27 expression in 84 human breast
carcinomas (sample set B). (a–f) Immunohistochemical stains for p27
(a, c, and e) and Skp2 (b, d, and f) of three breast carcinomas repre-
sentative of the three patterns of Skp2/p27 expression. The carcino-
ma in the top row shows high p27 expression in both the residual nor-
mal duct in the center and in the infiltrating tumor surrounding it (a).
Only one Skp2-positive cell is seen in the corresponding section in b.
The tumor in the middle panel shows a p27-negative tumor (with pos-
itive residual normal ducts) (c). Strongly positive Skp2 tumor cells are
seen in d. (e) Tumor that is negative for p27 (positive infiltrating lym-
phocytes are seen on the right). This tumor is also negative for Skp2
(f). (g) Graphic representation of the expression of Skp2 and p27 in
the 84 tumors. Using the cutoffs (50% for p27 and 10% for Skp2) to
define high and low expressors, tumors fall into three categories: high
p27/low Skp2, low p27/high Skp2, and low p27/low Skp2.
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Skp2 is required for anchorage independence in breast can-
cer cells. The results in human breast cancers suggest
that high Skp2 expression might contribute to onco-
genesis in breast epithelium. We have shown recently
that in primary diploid fibroblasts Skp2 expression
requires cell adhesion to the ECM (23) (see also Figure
4b, lanes 1–3). We determined whether the requirement
of cell adhesion for the expression of Skp2 is also pres-
ent in breast epithelial cells. Monolayer cultures of nor-
mal HBECs were trypsinized and replated in suspen-
sion. Under these conditions, the overall amount of
Skp2 dramatically decreased by 12 hours, which corre-
sponded to an accumulation of p27 (Figure 4a, lanes
1–3) and a cell cycle arrest (not shown). In contrast,
MCF-7 cells (ER-positive), two ER-negative breast cell
lines (HBL-100 and MDM-MB-435), and other trans-
formed cell lines expressed the same levels of Skp2 and
p27 and proliferated regardless of their adhesion con-
ditions (Figure 4, a and b). Thus, transformed cell lines
have lost an adhesion-dependent control of Skp2 that
is still present in normal cells. To determine if this
deregulation of Skp2 expression is linked to the trans-
formed phenotype of cancer cells, we infected MCF-7
and MDM-MB-435 cells with a retroviral vector
expressing either Skp2 or a Skp2 dominant-negative
mutant missing the F-box [Skp2(∆F)] (13). Infected
cells were then monitored for their ability to grow in an
anchorage-independent manner by forming colonies in
soft agar. While Skp2 expression did not have any sig-
nificant effect, the expression of Skp2(∆F) mutant
strongly inhibited the growth in soft agar of these two
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Figure 3
Correlation between Skp2 and proliferative index in sample set B. (a–d) Immunohistochemical stains of two representative breast carcino-
mas with anti-Skp2 (a and c) and anti-Ki67 (b and d) Ab’s. The tumor in the top row shows high Skp2/high Ki-67 levels. The one in the bot-
tom row displays low Skp2/low Ki67 levels. (e) Graphic representation of the direct correlation between Skp2 expression and proliferative
index in the 37 breast carcinomas. (f–k) Dual immunofluorescence of Skp2 with Ki67 in the breast cancer cell line MCF7 and in breast car-
cinomas. In MCF-7 cells (f, g, and h) as well as in breast carcinoma samples (i, j, and k), Skp2 protein (Texas Red) was detected only in cells
expressing Ki67 (FITC). Both Ki67 and Skp2 are localized in the nucleus. A subset of cells that expressed Ki67 protein was negative for Skp2
expression (h and k).
Figure 4
Expression of Skp2 is required for anchorage independence in breast
epithelial cancer cells. (a) Proliferating normal HBECs (lanes 1–3),
three different breast cell lines (lanes 4–12), (b) normal human fibrob-
lasts (lanes 1–3), and other transformed cell lines (lanes 4–12) were
trypsinized and replated in suspension. Cells were collected at the indi-
cated times, and protein extracts were analyzed by immunoblotting
with Ab’s to the indicated proteins. (c) Comparative analysis of the
number of colonies larger than 200 µM in diameter obtained growing
breast cancer cells infected with various retroviruses in soft-agar. A
total of 105 MCF-7 cells or 5 × 103 MDM-MB-435 cells were seeded in
0.3% agar supplemented in 5% calf serum. Colonies were scored after
3 weeks of growth. The number of colonies scored represented at least
three independent experiments ± the SD of the mean.
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cell lines (Figure 4c). These results show that the inhi-
bition of Skp2, in both ER-positive and ER-negative
cells, results in a suppression of tumor growth and sug-
gest that Skp2 is a target of therapies aimed at inhibit-
ing the growth of breast carcinomas.
Skp2 expression abrogates antiestrogen-mediated cell cycle
arrest in hormone-dependent breast epithelial cancer cells.
Although most ER-negative tumors display higher lev-
els of Skp2 (67% as determined by immunohistochem-
istry and 61% by microarray), a fraction of ER-positive
tumors also has higher Skp2 expression (15% as deter-
mined by immunohistochemistry and 23% by microar-
ray). This finding prompted us to study the relation-
ship between estrogens and Skp2 expression. Thus, we
assessed the estrogen-mediated cell cycle regulation of
Skp2 in the well-characterized human breast MCF-7
cell line, which is estrogen sensitive. Asynchronous
MCF-7 cells were arrested in G1 by treatment with
tamoxifen combined with estrogen deprivation, as
monitored by the downregulation of cyclin A levels and
Cdk2 activity (Figure 5a, third panel from the top and
bottom panel, respectively, lanes 1–3). Similar to cyclin
A, the total abundance of Skp2 significantly decreased
during cell cycle exit in parallel with an increase in p27
abundance (Figure 5a, top two panels, lanes 1–3). When
cells were restimulated to enter the cell cycle by the sole
addition of 17-β estradiol, Skp2 protein abundance
increased in parallel with a decrease in p27 levels (Fig-
ure 5a, top two panels, lanes 4–6). In contrast, levels of
cyclin D1 (Figure 5a, third panel from the top) and
cyclin E (data not shown) did not change significantly
in tamoxifen- and estradiol-treated cells. Thus, estro-
gens acting as mitogens in MCF-7 cells induce cell cycle
re-entry and consequently Skp2 upregulation.
We then studied the phenotype of MCF-7 cells con-
stitutively expressing either Skp2, cyclin D1, or cyclin E
singularly, or Skp2 and cyclin D1 simultaneously. To
express these proteins in MCF-7 cells, we used retroviral
expression vectors and found that Skp2, cyclin D1, and
cyclin E were all expressed in an estradiol- and tamox-
ifen-independent manner at levels two- to fourfold
higher than those of the respective endogenous proteins
(data not shown). Infected cells were either left asyn-
chronous or were synchronized in G1 by tamoxifen
treatment and estrogen deprivation. Percentage of cells
in S-phase was then analyzed by BrdU incorporation
(Figure 5b). No significant differences in BrdU incor-
poration were observed in untreated cells infected with
either Skp2 or G1 cyclins. In contrast, significant dif-
ferences were observed in tamoxifen-treated cells. In
fact, compared with control cells, a significant increase
in BrdU incorporation was observed in Skp2-expressing
cells. In agreement with previous published results, a
significant but more modest effect was also observed in
cyclin D1–expressing cells, but not in cyclin E–express-
ing cells. These results show that the enforced expres-
sion of Skp2 in hormone-dependent breast cancer cells
confer resistance to a G1 arrest mediated by antiestro-
gens and estrogen deprivation. Thus, in ER-positive
breast carcinomas treated with antiestrogens, deregu-
lated Skp2 expression might play a relevant role in the
development of resistance to these drugs.
Discussion
This study provides insights into the oncogenic role of
Skp2 in human breast cancer. Using microarray
hybridization of RNA from 89 breast carcinomas (sam-
ple set A), we found that Skp2 message is overexpressed
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Figure 5
Enforced expression of Skp2 abrogates antiestrogen-mediated cell
cycle arrest in MCF-7 cells. (a) MCF-7 breast cancer cells were syn-
chronized in G1 phase by treatment with 1 µM tamoxifen for the
indicated times (lanes 1–3). The cells were then restimulated to enter
the cell cycle by addition of 500 nM estradiol for the indicated times
(lanes 4–6). Cell extracts were analyzed by immunoblotting with Ab’s
to the indicated proteins (top four panels) and for Cdk2 kinase activ-
ity assayed using histone H1 (HH1) as a substrate after immuno-
precipitation of Cdk2 (bottom panel). (b) MCF-7 cells infected with
retroviruses expressing the indicated proteins were either left asyn-
chronous or were synchronized in G1 by depletion of estradiol and
treated with tamoxifen for 48 or 96 hours, as indicated. The per-
centage of MCF-7 cells in S-phase was then analyzed by BrdU incor-
poration. The results shown in the first 10 bars are the mean per-
centage obtained from at least three independent experiments.
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in a subset of high-grade ductal carcinomas that are neg-
ative for ER expression and do not overexpress Her-2
(Figure 1). The inverse correlation between Skp2 and ER
protein levels, as well as the direct correlation between
Skp2 levels and tumor grade, was confirmed by
immunohistochemistry in a second series of 84 breast
cancers (sample set B) (Figure 2). Interestingly, our gene
expression analysis also demonstrates that tumors over-
expressing Skp2 are negative for keratins characteristic
of epithelial luminal cells but show the expression of
epithelial basal cell markers, including keratins 5 and 17
(Figure 1). A similar subtype of ER/Her-2–negative
breast tumors with basal-like phenotype has been iden-
tified recently and found to be associated with poorer
outcome as compared with the ER-positive subgroups
of tumors with luminal phenotypes (3, 4). Accordingly,
when we assessed the relationship between Skp2 and
survival in sample set B, we found that high levels of
Skp2 were associated with poor survival by univariate
analysis. Larger series of tumors will have to be analyzed
to determine the independent prognostic significance of
Skp2 in breast cancer.
While in certain tumors p27 is inactivated by cyto-
plasmic sequestration or by oncoproteins such as Myc
and E1a through still not well-understood mecha-
nisms, reduced protein levels of the cell cycle inhibitor
p27 are frequently observed in a variety of human
tumors and are associated with poor prognosis
(reviewed in ref. 17). In breast carcinomas we and other
investigators have shown previously that loss of p27
expression in tumor cells is an independent predictor
of both overall survival and disease-free survival
(28–30). In agreement with the role of Skp2 in p27
degradation, we found that Skp2 levels inversely corre-
late with p27 expression (Figure 2). An interesting find-
ing was the fact that in a subset of breast cancers, Skp2
was expressed at low levels despite low expression of
p27. This could be due to low levels but hyperactive
Skp2 (e.g., because of mutations, overexpression of the
Skp2-cofactor Cks1, etc.). Alternatively, in these tumors
p27 downregulation could be due to other, as yet
unknown, mechanisms. We also found that breast
tumors expressing high Skp2 are characterized by high
expression of markers of both S-phase and G2/M at
both RNA and protein levels. In addition, we show that
in both human cancers and breast cancer cells in cul-
ture, Skp2 protein is selectively expressed in a subset of
proliferating cells (Figure 3). Remarkably, among the
three different D-type cyclins, only cyclin D3 clustered
with Skp2. These data confirm previous data showing
positive correlation between cyclin D3 and high tumor
grade (36). As expected, cyclin D1 was predominantly
expressed in ER-positive, low-grade cancers (37). Inter-
estingly, a recent study of gene expression profiling in
breast cancer has identified genes regulating cell cycle
to be one of the defining clusters of the molecular sig-
nature of poor prognosis (38).
Overall, our analysis in human tumors, taken togeth-
er with the results present in the literature, demonstrate
the existence of a subtype of high-grade, highly prolif-
erating ER/Her-2–negative breast carcinomas with a
basal-like phenotype characterized by high Skp2 and
low p27 levels. These observations lead to the hypothe-
sis that Skp2 overexpression plays a relevant role in the
pathogenesis of this subset of tumors by providing a
growth advantage, perhaps by promoting p27 degrada-
tion. We investigated the oncogenic potential of Skp2
and found that, in contrast to normal epithelial cells, in
breast cancer cells Skp2 expression is not altered by loss
of adhesion to the cell matrix (Figure 4a). This finding
suggests a role for Skp2 in the adhesion-independent
ability of tumor cells to grow, and, in fact, inhibition of
Skp2 activity reduces the adhesion-independent growth
ability of cancer cells, as measured by the number of
colonies in soft agar (Figure 4b). The effects produced
by Skp2 inhibition are independent of the presence of
the ER since they are observed both in ER-positive
(MCF-7) and ER-negative cells (MDM-MB-435, which
express very low levels of Her-2) (39).
Interestingly, while a specific therapy with anti-Her-2
Ab’s (Herceptin) is currently used in ER-negative breast
cancer that overexpresses Her-2 (2), no specific therapy
has been identified in those tumors that are both ER and
Her-2 negative. Since Skp2 expression is associated with
lack of both ER and Her-2, and Skp2 inhibition affects
the in vitro growth of ER/Her-2–negative breast cancer
cells, our study identifies Skp2 as a potential specific
therapeutic target in this subset of aggressive breast can-
cers. Finally, we show that enforced expression of Skp2
induces resistance to antiestrogens (Figure 5b). Albeit
much less than in ER-negative tumors, where Skp2 is
highly expressed in 61–67% of cases, Skp2 is also
expressed at higher levels in 15% (as detected by
immunohistochemistry) to 23% (as detected by microar-
ray) of the ER-positive tumors. Thus, it is tempting to
speculate that Skp2 overexpression may be one of the
factors implicated in the lack of response to hormonal
therapy, which occurs in roughly one-third of tumors
expressing ER. Similarly, it is possible to infer that dereg-
ulated Spk2 expression in ER-positive tumors treated
with antihormonal therapy may play an important role
in the development of resistance to antiestrogens.
In summary, our results support the notion that Skp2
is the product of a proto-oncogene and indicate that an
alteration of Skp2 function and expression might con-
tribute to the malignant behavior of breast tumors.
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